| Literature DB >> 25911052 |
N Daneman1, A Guttmann2, X Wang3, X Ma3, D Gibson4, T A Stukel5.
Abstract
BACKGROUND: Clostridium difficile is the most common cause of healthcare-acquired infection; the real-world impacts of some proposed C. difficile prevention processes are unknown.Entities:
Keywords: Health services research; Healthcare quality improvement; Infection control; Nosocomial infections
Mesh:
Year: 2015 PMID: 25911052 PMCID: PMC4484271 DOI: 10.1136/bmjqs-2014-003863
Source DB: PubMed Journal: BMJ Qual Saf ISSN: 2044-5415 Impact factor: 7.035
Clostridium difficile prevention processes across Ontario acute care hospitals
| General | Specific | All hospitals | Academic/ teaching N=17 | Large community | Medium community | Small community |
|---|---|---|---|---|---|---|
| Infection control | Isolation at onset of diarrhoea | 43 (27%) | 10 (59%) | 6 (27%) | 3 (13%) | 24 (25%) |
| Antibiotic stewardship | Audit of antibiotic use | 26 (16%) | 6 (35%) | 6 (27%) | 4 (17%) | 10 (10%) |
| Environmental cleaning | Audit of cleaning practices | 115 (72%) | 15 (88%) | 20 (91%) | 18 (78%) | 62 (64%) |
| Diagnosis | On-site diagnostic testing | 74 (47%) | 11 (65%) | 15 (68%) | 13 (57%) | 35 (36%) |
| Treatment | Vancomycin as first-line treatment | 24 (15%) | 4 (24%) | 0 (0%) | 2 (9%) | 18 (19%) |
| Leadership | Reporting to senior leadership | 52 (33%) | 6 (35%) | 6 (27%) | 5 (22%) | 35 (36%) |
Baseline characteristics among patient admissions with versus without Clostridium difficile infection
| No | ||
|---|---|---|
| Age group (years) | ||
| 1–10 | 26 063 (4.0%) | 28 (1.2%) |
| 11–17 | 18 523 (2.8%) | 23 (1.0%) |
| 18–44 | 210 095 (32.2%) | 189 (8.1%) |
| 45–64 | 149 632 (23.0%) | 454 (19.4%) |
| 65–74 | 90 108 (13.8%) | 389 (16.6%) |
| 75–84 | 96 533 (14.8%) | 674 (28.8%) |
| ≥85 | 60 601 (9.3%) | 584 (24.9%) |
| Female sex | 403 609 (61.9%) | 1371 (58.6%) |
| Admission type | ||
| Medical | 266 943 (41.0%) | 1909 (81.5%) |
| Surgical | 218 267 (33.5%) | 379 (16.2%) |
| Obstetrical or other | 166 345 (25.5%) | 53 (2.3%) |
| Elective admission | 253 736 (38.9%) | 202 (8.6%) |
| Infection as most responsible diagnosis | 48 847 (7.5%) | 262 (11.2%) |
| Previous diagnoses | ||
| Myocardial infarction | 27 173 (4.2%) | 155 (6.6%) |
| Congestive heart failure | 30 741 (4.7%) | 346 (14.8%) |
| Peripheral vascular disease | 9782 (1.5%) | 102 (4.4%) |
| Cerebrovascular disease | 20 431 (3.1%) | 144 (6.2%) |
| Dementia | 20 015 (3.1%) | 241 (10.3%) |
| Chronic obstructive pulmonary disease | 38 879 (6.0%) | 286 (12.2%) |
| Rheumatological disease | 3951 (0.6%) | 35 (1.5%) |
| Peptic ulcer disease | 4450 (0.7%) | 57 (2.4%) |
| Diabetes mellitus | 91 592 (14.1%) | 572 (24.4%) |
| Hemiparesis/paraplegia | 55 749 (8.6%) | 294 (12.6%) |
| Renal disease | 7290 (1.1%) | 88 (3.8%) |
| Malignancy | 3955 (0.6%) | 48 (2.1%) |
| Liver disease | 15 616 (2.4%) | 200 (8.5%) |
| Inflammatory bowel disease | 4913 (0.8%) | 43 (1.8%) |
| HIV or other immunocompromise | 4934 (0.8%) | 66 (2.8%) |
| Healthcare exposure in preceding 8 weeks | ||
| Hospital admission* | 9571 (1.5%) | 139 (5.9%) |
| Emergency department visit | 194 621 (29.9%) | 1161 (49.6%) |
| Past gastrointestinal procedure | 17 499 (2.7%) | 104 (4.4%) |
| Same-day surgery procedure | 36 206 (5.6%) | 152 (6.5%) |
| Nursing home stay | 1851 (0.3%) | 27 (1.2%) |
| Haemodialysis | 4192 (0.6%) | 53 (2.3%) |
| Chemotherapy | 11 060 (1.7%) | 73 (3.1%) |
| Homecare treatment | 79 564 (12.2%) | 723 (30.9%) |
| Recent diagnosis of infection | 196 828 (30.2%) | 1190 (50.8%) |
| Calendar month of admission | ||
| January | 49 975 (7.7%) | 164 (7.0%) |
| February | 47 838 (7.3%) | 169 (7.2%) |
| March | 50 275 (7.7%) | 156 (6.7%) |
| April | 66 767 (10.2%) | 353 (15.1%) |
| May | 63 047 (9.7%) | 256 (10.9%) |
| June | 59 250 (9.1%) | 231 (9.9%) |
| July | 54 464 (8.4%) | 198 (8.5%) |
| August | 52 474 (8.1%) | 204 (8.7%) |
| September | 52 995 (8.1%) | 138 (5.9%) |
| October | 52 780 (8.1%) | 164 (7.0%) |
| November | 51 594 (7.9%) | 157 (6.7%) |
| December | 50 096 (7.7%) | 151 (6.5%) |
| Hospital type | ||
| Academic/teaching | 207 942 (31.9%) | 746 (31.9%) |
| Large community | 248 377 (38.1%) | 869 (37.1%) |
| Medium community | 118 463 (18.2%) | 497 (21.2%) |
| Small community | 76 773 (11.8%) | 229 (9.8%) |
| Proportion of beds in single-bed rooms | ||
| <25% | 193 195 (29.7%) | 638 (27.3%) |
| 25%–35% | 81 843 (12.6%) | 324 (13.8%) |
| >35% | 245 677 (37.7%) | 890 (38.0%) |
| Not available | 130 840 (20.1%) | 489 (20.9%) |
| Hospital processes of care | ||
| Immediate isolation for patients with diarrhoea | 222 265 (34.1%) | 735 (31.4%) |
| Audit of compliance for antibiotic stewardship | 195 921 (30.1%) | 748 (32.0%) |
| Audit of compliance of environmental cleaning | 562 104 (86.3%) | 2102 (89.8%) |
| Reporting to CEO or hospital board | 217 603 (33.4%) | 739 (31.6%) |
| On-site | 428 694 (65.8%) | 1482 (63.3%) |
| Use of vancomycin as first-line treatment | 73 284 (11.2%) | 288 (12.3%) |
*The study involved only the first hospital admission per patient in the study year, but patients enrolled in the first 8 weeks of the study period could have been hospitalised at the end of the preceding year.
CEO, chief executive officer.
Multivariable binary generalised estimating equations (GEE) regression modelling the impact of patient and hospital-level predictors on the patient-level risk of Clostridium difficile infection
| Adjusted OR | 95% CI | p Value | |
|---|---|---|---|
| Age group (years) | |||
| 1–10 | 0.15 | 0.07 to 0.31 | <0.001 |
| 11–17 | 0.19 | 0.10 to 0.39 | <0.001 |
| 18–44 | 0.52 | 0.44 to 0.62 | <0.001 |
| 45–64 | 0.61 | 0.54 to 0.69 | <0.001 |
| 65–74 | 0.77 | 0.68 to 0.87 | <0.001 |
| 75–84 | 1.00 | 1.00 | 1.00 |
| ≥85 | 1.12 | 1.00 to 1.26 | 0.05 |
| Female sex | 1.28 | 1.18 to 1.40 | <0.001 |
| Admission type | |||
| Medical | 2.30 | 2.01 to 2.64 | <0.001 |
| Obstetrical | 0.04 | 0.015 to 0.091 | <0.001 |
| Surgical | 1.00 | 1.00 | 1.00 |
| Other | 2.52 | 1.29 to 4.92 | 0.007 |
| Elective admission | 0.55 | 0.46 to 0.65 | <0.001 |
| Infection as most responsible diagnosis | 0.90 | 0.78 to 1.02 | 0.10 |
| Previous diagnoses | |||
| Myocardial infarction | 0.85 | 0.72 to 1.01 | 0.06 |
| Congestive heart failure | 1.41 | 1.24 to 1.59 | <0.001 |
| Peripheral vascular disease | 2.11 | 1.72 to 2.58 | <0.001 |
| Cerebrovascular disease | 0.93 | 0.77 to 1.12 | 0.42 |
| Dementia | 1.39 | 1.20 to 1.60 | <0.001 |
| Chronic obstructive pulmonary disease | 1.17 | 1.03 to 1.33 | 0.014 |
| Rheumatological disease | 1.55 | 1.10 to 2.18 | 0.012 |
| Peptic ulcer disease | 2.05 | 1.57 to 2.68 | <0.001 |
| Diabetes mellitus | 1.03 | 0.93 to 1.14 | 0.57 |
| Hemiparesis/paraplegia | 2.04 | 1.49 to 2.79 | <0.001 |
| Renal disease | 1.44 | 1.23 to 1.69 | <0.001 |
| Malignancy | 1.18 | 1.03 to 1.35 | 0.020 |
| Liver disease | 2.05 | 1.64 to 2.56 | <0.001 |
| HIV | 1.56 | 0.50 to 4.91 | 0.45 |
| Inflammatory bowel disease | 2.43 | 1.78 to 3.32 | <0.001 |
| Other immunocompromise | 2.19 | 1.67 to 2.88 | <0.001 |
| Healthcare exposure in preceding 8 weeks | |||
| Hospital admission | 1.64 | 1.31 to 2.05 | <0.001 |
| Emergency department visit | 0.80 | 0.53 to 1.21 | 0.29 |
| Past gastrointestinal procedure | 1.15 | 0.91 to 1.46 | 0.24 |
| Same-day surgery procedure | 1.07 | 0.88 to 1.30 | 0.49 |
| Nursing home stay | 1.08 | 0.73 to 1.60 | 0.71 |
| Haemodialysis | 1.29 | 0.96 to 1.75 | 0.09 |
| Chemotherapy | 0.89 | 0.68 to 1.15 | 0.37 |
| Homecare treatment | 1.37 | 1.25 to 1.52 | <0.001 |
| Recent diagnosis of infection | 1.56 | 1.02 to 2.38 | 0.038 |
| Calendar month of admission | |||
| January | 0.93 | 0.75 to 1.14 | 0.49 |
| February | 1.03 | 0.84 to 1.26 | 0.80 |
| March | 0.90 | 0.73 to 1.11 | 0.31 |
| April | 1.08 | 0.90 to 1.29 | 0.42 |
| May | 0.96 | 0.79 to 1.15 | 0.64 |
| June | 1.03 | 0.85 to 1.24 | 0.78 |
| July | 1.00 | 1.00 | 1.00 |
| August | 1.06 | 0.87 to 1.29 | 0.59 |
| September | 0.75 | 0.60 to 0.93 | 0.01 |
| October | 0.90 | 0.73 to 1.11 | 0.32 |
| November | 0.87 | 0.70 to 1.07 | 0.18 |
| December | 0.85 | 0.69 to 1.06 | 0.15 |
| Hospital type | |||
| Academic/teaching | 2.13 | 1.55 to 2.93 | <0.001 |
| Large community | 1.83 | 1.38 to 2.42 | <0.001 |
| Medium community | 1.77 | 1.38 to 2.36 | <0.001 |
| Small community | 1.00 | 1.00 | 1.00 |
| Proportion of beds in single-bed rooms | |||
| <25% | 1.00 | 1.00 | 1.00 |
| 25%–35% | 1.16 | 0.86 to 1.55 | 0.34 |
| >35% | 1.16 | 0.92 to 1.47 | 0.21 |
| Not available | 1.13 | 0.82 to 1.55 | 0.45 |
| Baseline | 1.02 | 1.01 to 1.03 | 0.010 |
| Testing method for | |||
| Standard culture followed by cytotoxin assay | 0.90 | 0.66 to 1.22 | 0.49 |
| PCR | 1.40 | 1.03 to 1.91 | 0.03 |
| Toxin A/B testing by commercial enzyme assay | 0.92 | 0.66 to 1.30 | 0.65 |
| Other | 1.00 | 1.00 | 1.00 |
| Hospital processes of care | |||
| Immediate isolation for patients with diarrhoea | 0.93 | 0.66 to 1.22 | 0.56 |
| Audit of compliance for antibiotic stewardship | 1.17 | 0.92 to 1.50 | 0.20 |
| Audit of compliance of environmental cleaning | 1.29 | 0.99 to 1.67 | 0.06 |
| Reporting to CEO or hospital board | 0.97 | 0.77 to 1.21 | 0.78 |
| On-site | 0.87 | 0.68 to 1.10 | 0.24 |
| Use of vancomycin as first-line treatment | 1.19 | 0.87 to 1.63 | 0.28 |
CEO, chief executive officer.